Who is Anastasios Kamoutsas? DeSantis makes pick for Florida Commissioner of Education
On June 3, he recommended one of his top aides , deputy chief of staff Anastasios Kamoutsas, for the job to replace former commissioner Manny Diaz Jr., who was elected a week prior to be interim president of the University of West Florida.
'Stasi Kamoutsas has delivered on important issues like parental rights, school choice, and fighting back against radical ideologies in education,' DeSantis said in a release. 'I am confident that he will continue to serve our state well as the next Commissioner of Education, and I thank Commissioner Manny Diaz Jr. for his dedicated and productive service.'
Diaz, the latest in a line of DeSantis allies put in charge of higher education institutions in Florida, was delighted with the choice. "Great pick Governor!" he posted on X. "Stasi will be a huge advocate for students and families in Florida."
The State Board of Education is meeting Wednesday, June 4, at 10:30 a.m. to consider appointing a commissioner.
Anastasios I. Kamoutsas, 36, has a fairly low-profile presence, but he has been involved in many of DeSantis' key initiatives and was described by Florida Politics as "one of the most feared staffers."
Kamoutsas, who holds a bachelor of arts in political science from Florida International University and his juris doctor from Regent University School of Law, a private Christian university. He joined the Florida Department of Education in 2019 to be general counsel and then chief of staff during the state's battle against mandated COVID masks in schools before he was tapped to be one of DeSantis' deputy chiefs of staff.
'Under my tenure, the Florida Department of Education will remain committed to student safety and success, empowering parents, and supporting teachers,' Kamoutsas said in DeSantis' press release. 'I look forward to working with the State Board of Education to ensure that Florida remains the education state.'
While most of his work has been behind the scenes, Kamoutsas has popped up in the news.
NBC News reported in March that Kamoutsas was one of DeSantis' aides who had made calls to state lobbyists, asking them not to donate to Florida 2026 gubernatorial candidate Rep. Byron Donalds. First lady Casey DeSantis has not announced her own run, but has been rumored to be considering it for months. Kamoutsas denied NBC's allegations.
He was also named in 2023 as the person who called then-FDLE Chief of Staff Shane Desguin to deny the promotion and raise for an attorney who disagreed with DeSantis' aides about what parts of the governor's travel records were public information because she "was not on our team," according to former FDLE deputy chief of staff Patricia Carpenter.
When Desguin asked if he could give Robinson another position and salary increase, he 'was told 'no, she is lucky she even has a f—ing job,'' Carpenter said, according to The News Service of Florida. Carpenter was fired after she sought whistleblower protection.
Last October, Kamoutsas raised a stink in his homeowner's association in Tallahassee for posting signs against a proposed abortion amendment on his lawn and reportedly gaming HOA rules by removing them before a meeting, avoiding hundreds of dollars in fines, and then replacing and increasing them the next day.
Kamoutsas' wife is a lawyer for the State University System.
Diaz was selected to replace UWF president Martha Saunders, who chose to step down after a contentious board of trustees meeting where newly appointed member Zach Smith grilled her about "diversity, equity and inclusion" issues he had identified when combing through UWF's social media. Smith had been appointed by DeSantis days earlier.
Diaz joins a growing rank of DeSantis allies to head universities and colleges in Florida as the governor continues to leave his mark on education in the Sunshine State.
On June 2, Jeanette Nuñez, formerly DeSantis' lieutenant governor, was named president of Florida International University. The appointment remains subject to approval by the state university system's Board of Governors.
Marva Johnson, who served as a political appointee in the administrations of Governors Rick Scott and Ron DeSantis, was picked in May to be president of Florida A&M University despite massive and sustained objections from the FAMU community of students, teachers and alumni.
Richard Corcoran was the state commissioner of education and one of Desantis' most dependable and effective supporters when he was named president of New College of Florida as part of the governor's efforts to overhaul the liberal arts college into a conservative institution.
Contributing: Mary Lett, Pensacola News Journal
This article originally appeared on Tallahassee Democrat: DeSantis picks Florida education commissioner. What to know
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


NBC News
2 minutes ago
- NBC News
Target names longtime insider Michael Fiddelke its next CEO as retailer tries to break sales and stock slump
Target on Wednesday said that company veteran Michael Fiddelke will become its next CEO at a critical point in its effort to break out of a sales slump and win back Wall Street's favor. Fiddelke, the company's 49-year-old chief operating officer and former chief financial officer, will succeed Brian Cornell effective Feb. 1. Cornell, who took the helm of the cheap chic retailer in 2014, will transition to the role of executive chair on Target's board of directors. The Minneapolis-based retailer made the announcement on the same day it reported fiscal second-quarter results. It topped Wall Street's quarterly sales and earnings expectations, but stuck by a full-year outlook that forecasts another annual sales decline. Target shares dropped about 10% in premarket trading after the company made the CEO announcement and released results. Before Target announced its choice, Wall Street appeared to favor an outsider for the top job. Fiddelke steps into Target's top role as the big-box retailer tries to find its footing and get back to growth. Target's annual sales have been roughly flat for the past four years after the company's sales soared during the Covid pandemic. On a call with reporters, Fiddelke said he is 'stepping in with urgency to rebuild momentum and return to profitable growth.' He laid out three priorities: Reestablishing Target's reputation as a retailer with stylish and unique items, providing a more consistent customer experience and using technology more effectively to operate an efficient business. 'We've built a solid foundation, and we're proud of the many ways that Target is unique in American retail,' he said. 'We also have real work in front of us.' Fiddelke is a 20-year Target veteran. During his decades with the company, he has held leadership roles across merchandising, finance, operations and human resources. He became Target's chief financial officer in late 2019 and stepped into the role of chief operating officer in early 2024. In May, he was tapped to oversee a new effort, the Enterprise Acceleration Office, created to turn around Target's results. Target cut its full-year outlook in May and reiterated that guidance on Wednesday, saying that it expects a low-single-digit percentage point decline in sales this fiscal year. Target's performance has shaken Wall Street's confidence. Shares of the company have tumbled about 60% since their all-time high in 2021. Target's stock had dropped 22% in 2025 alone as of Tuesday's close. Customers, former employees and suppliers told CNBC that the company's best-known traits of eye-catching merchandise, tidy stores and friendly employees have become weaker. The retailer also is facing stiffer competition from rivals including Walmart, contending with cost pressures because of tariffs and dealing with backlash to its reversal of key diversity, equity and inclusion policies. And last week, Ulta Beauty and Target announced they are ending a deal that opened mini beauty shops in nearly a third of Target's stores. The partnership will end in August 2026. Wall Street had favored an outsider for the CEO job, according to a June survey of 51 investors by Mizuho Securities, an equity research firm. About 96% of investors polled favored an external hire for Target's next CEO. Christine Leahy, lead independent director of Target's board of directors, said in a news release that the board chose Fiddelke after 'an extensive external search and assessment of many strong candidates' over several years. 'Michael's tenure gives him unmatched enterprise insight and a base of strong team trust,' she said. 'But what sets him apart is how he combines those strengths with a 'fresh eyes' mindset, challenging the status quo to evolve how the business operates, differentiates and delivers long-term value.' On a call with reporters, Cornell and Fiddelke were asked what they would say to investors who had hoped for Target to hire an outsider who would bring fresh ideas. Fiddelke answered the question. 'I understand this business,' he said. 'I understand what makes Target distinctly unique. And I've seen us at our best, and I've seen us when we're not at our best, and that informs my candid assessment today of where we have work to do as well.' 'But I'll go back to some of what I started with: My number one goal is to get us back to growth.'


Business Wire
31 minutes ago
- Business Wire
Nucleus RadioPharma Appoints Former FDA Commissioner Dr. Stephen Hahn as CEO to Scale Patient Access to Radiopharmaceutical Therapies
ROCHESTER, Minn.--(BUSINESS WIRE)-- Nucleus RadioPharma, a next-generation contract development and manufacturing organization (CDMO) specializing in radiopharmaceuticals, today announced the appointment of Dr. Stephen M. Hahn as chief executive officer. Hahn's leadership signals Nucleus RadioPharma's urgency in scaling the infrastructure necessary to make minimally invasive, targeted cancer therapies accessible to patients around the world. Hahn joins Nucleus RadioPharma after serving as CEO-partner of Flagship Pioneering and CEO of Harbinger Health since 2021. He served as the 24th U.S. Food and Drug Administration (FDA) commissioner from 2019 to 2021, overseeing both COVID and non-COVID regulatory affairs. Before joining the FDA, he was the chief medical executive at MD Anderson Cancer Center in Houston. The combination of regulatory, clinical and operational knowledge gives him deep insight into how therapies move from clinic to patient. Radiopharmaceuticals represent one of the most promising frontiers in oncology, offering treatments that are less toxic, less invasive and far more precise in targeting cancer cells. When patients receive these therapies, outcomes improve and quality of life is preserved. However, widespread access to radiopharmaceuticals remains extremely limited, not due to scientific barriers, but logistical ones. Three interdependent issues drive these supply chain challenges: a fragile and insufficient supply of key isotopes, limited GMP-compliant infrastructure capable of handling a range of medical isotopes and an underdeveloped operational capacity to manage radioactive drugs. 'Radiopharmaceuticals are the next frontier of precision oncology care,' said Hahn. 'But without the infrastructure to deliver these treatments, their impact is fundamentally limited. At Nucleus RadioPharma, we have an extraordinary team that is committed to breaking those barriers. Together, we will scale the systems and infrastructure needed to make these lifesaving therapies available to all who need them.' Under Hahn's leadership, Nucleus RadioPharma is uniquely positioned to tackle these issues, take radiopharmaceuticals to new levels of precision and efficacy and make minimally invasive therapies the new standard for cancer treatment. 'Steve's experience as both a physician treating patients and as a leader at the FDA brings an unparalleled perspective to Nucleus as the company works to build the infrastructure needed to accelerate the widespread availability of radiopharmaceuticals,' said Justin Butler, partner at Eclipse and Nucleus board member. 'His new role is a major indicator to the oncology community that radiopharmaceuticals are the future of precision cancer treatment, and that Nucleus is poised to lead the next era.' Founded in 2022 through a collaboration between Eclipse and Mayo Clinic, Nucleus has raised $72 million in funding to date, including participation from AstraZeneca. The company is building a network of advanced facilities, starting in Mesa, Arizona, and Spring House, Pennsylvania, that integrate research, development and commercial-scale production under one roof, enabling faster, more reliable distribution to clinical trial sites and treatment centers. 'With one of the largest cancer theranostics practices in the world, we have a responsibility to drive continual innovation and develop new targeted diagnostic and therapeutic radioisotopes for our patients,' said Dr. Cheryl Willman, Stephen and Barbara Slaggie executive director for Mayo Clinic Cancer Programs and Mayo Clinic Comprehensive Cancer Center. 'With Steve's exemplary leadership skills and expertise as a cancer physician and scientist, our future could not be brighter.' In his first year as CEO, Hahn will focus on completing the company's GMP readiness at its Rochester, Minnesota, facility, expanding R&D capabilities, launching Nucleus' data platform and forging strategic partnerships. Over the next five years, the company aims to dramatically increase manufacturing capacity and advance initiatives that improve patient access worldwide. For more information on Nucleus RadioPharma, see here. Nucleus RadioPharma is an innovative CDMO dedicated to the development and manufacturing of targeted radiotherapies. With an emphasis on innovation and quality, Nucleus provides an array of services, from formulation and analytical development to regulatory documentation and drug product manufacturing. Its technology platforms are at the forefront of radiopharmaceutical research, designed to advance new therapies through clinical trials to commercialization. Learn more at


Business Wire
31 minutes ago
- Business Wire
SOSi Hires Former HSI Executive Andre Watson to Bolster Law Enforcement Partnerships
RESTON, Va.--(BUSINESS WIRE)-- SOSi announced today that it hired Andre R. Watson, the former Assistant Director for National Security at Homeland Security Investigations (HSI), as a Senior Account Executive to help expand its business and deliver capabilities to the federal and state law enforcement agencies. Watson has over two decades of global security risk management experience focused on domestic and international threat intelligence, counterterrorism, drug interdiction, border enforcement, and critical infrastructure protection. "Andre's interagency background and keen appreciation of threats to our national security make him a great addition to our team. I look forward to his helping us deliver data-driven intelligence and investigative analysis to our law enforcement customers," said Jim Edwards, SOSi Chief Growth Officer. As the former leader of the National Security Division (NSD) at HSI, Watson was responsible for counterterrorism, immigration system exploitation, counter-proliferation, and export control enforcement. He led numerous important initiatives, including global security tracking to counter weapons of mass destruction and coordinating the Department of Homeland Security (DHS) response to the Ebola virus and COVID-19 pandemic. He also drove collaboration among federal, state, and local agencies to combat global drug-related crimes and established natural disaster and emergency assistance rapid response teams in Washington, D.C. In addition to his various roles at HSI, Watson served as the Chief of Intelligence for International Organized Crime and Intelligence Operations (IOC-2) at the Department of Justice (DOJ). In that role, he marshaled resources and information across nine federal law enforcement agencies and federally led prosecutorial teams aimed at combating international organized criminal networks. The Center enabled pooled intelligence, synthesis of multi-agency data, and the generation of actionable leads and investigations. "My frontline perspective allows me to bridge the gap between SOSi's robust capabilities and the evolving requirements of the government agencies responsible for safeguarding our country," said Watson. SOSi has a long history of supporting federal law enforcement. The company's work with the U.S. Customs Service—the predecessor agency to Immigration and Customs Enforcement (ICE)—Drug Enforcement Administration (DEA), Federal Bureau of Investigation (FBI), and Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) dates back to its founding in 1989. Over the past 10 years, SOSi has also worked extensively with DOJ Executive Office for Immigration Review (EOIR), U.S. Border Patrol (USBP), and U.S. Customs and Border Protection (CBP). About SOSi Founded in 1989 and headquartered in Reston, Virginia, SOSi is a private defense and government services firm that is principally engaged in the research, design, development, integration, sustainment, and delivery of advanced technology systems, products, and services. Its capabilities include data science, software development, network engineering, intelligence, surveillance, and reconnaissance (ISR), and logistics.